Pertuzumab and trastuzumab emtansine in patients with HER2-amplified metastatic colorectal cancer: the phase II HERACLES-B trial

Pertuzumab and trastuzumab emtansine in patients with HER2-amplified metastatic colorectal cancer: the phase II HERACLES-B trial

Background HER2 is a therapeutic target for metastatic colorectal cancer (mCRC), as demonstrated in the pivotal HERACLES-A (HER2 Amplification for Colo-rectaL cancer Enhanced Stratification) trial with trastuzumab and lapatinib. The aim of HERACLES-B trial is to assess the efficacy of the combinatio...

Full description

Bibliographic Details
Main Authors: Sara Lonardi, Valter Torri, Fortunato Ciardiello, Andrea Sartore-Bianchi, Salvatore Siena, Silvia Marsoni, Alberto Bardelli, Francesca Bergamo, Cosimo Martino, Elisabetta Fenocchio, Federica Tosi, Silvia Ghezzi, Francesco Leone, Vittorina Zagonel, Andrea Ardizzoni, Alessio Amatu, Katia Bencardino, Emanuele Valtorta, Elena Grassi, Emanuela Bonoldi, Anna Sapino, Angelo Vanzulli, Daniele Regge, Giovanni Cappello, Livio Trusolino
Format: Article
Language:English
Published: Elsevier 2020-10-01
Series:ESMO Open
Online Access:https://esmoopen.bmj.com/content/5/5/e000911.full

Similar Items

Similar Items